BeneFIX Again Preventive Therapy for Children With Hemophilia B

BeneFIX Again Preventive Therapy for Children With Hemophilia B

306020

BeneFIX Again Preventive Therapy for Children With Hemophilia B

The U.S. Food and Drug Administration (FDA) has restored its approval of BeneFIX as a routine prophylactic, or preventive, treatment for bleeds in children and adolescents under 16 with hemophilia B. Marketed by Pfizer, BeneFIX is a lab-made version of factor IX (FIX), the blood clotting protein that is missing or defective in people with hemophilia B. The therapy is designed to control or prevent bleeds caused by its absence. BeneFIX was initially given FDA approval…

You must be logged in to read/download the full post.